Respiratory depression as side effect: should benzodiazepines be avoided
in patients with COVID-19?
AbstractThe pharmacological profile of benzodiazepines includes respiratory
depression, and theoretically benzodiazepines might contribute to
respiratory dysfunction. There are currently no data that indicate that
benzodiazepines are problematic in COVID-19, and the risk is expected to
be limited. Benzodiazepines are effective and frequently used, and if
there is a clear indication in patients with COVID-19 there is
insufficient reason to avoid benzodiazepines based on respiratory
depression as side effect.